Merck's RSV monoclonal antibody Claryrovimab commercially launched in China

According to Merck China, Merck (MRK.US) recently announced that the world's first single fixed-dose long-acting RSV monoclonal antibody, Clarryve monoclonal antibody injection, has officially been commercially launched in China. It is used for the prevention of lower respiratory tract infections caused by respiratory syncytial virus (RSV) in newborns and infants who are about to enter or are born during their first RSV season. There is no need to measure body weight; the same dosage is used for injection, providing a new option to help protect respiratory health for Chinese babies.